doi: 10.1042/BJ20120014 50 FoserSRedwanzIEbelingMHeizmannCWCertaU
Several intervention strategies were designed to affect HGF/c-Met signaling: inhibitors of HGF activation, HGF neutralizing antibodies Rilotumumab (AMG102), Ficlatuzumab (AV-299) and TAK701 [61], c-Met antagonists Onartuzumab, CE-355621, selective inhibitors of c-Met kinase activity Tivantinib, AMG-337, AMG-458, Foretinib, PHA-665725, MK-2461, PF-04217903 and SU11274, and nonselective multitarget inhibitors of RTK including c-Met such as Crizotinib and Cabozantinib
For peptides like BPC-157 or compounds related to TB-500 to become lawful prescription options, they would need: Controlled clinical trials Demonstrated safety and efficacy FDA approval Regulated manufacturing standards Until then, claims that these peptides are prescribable or approved are premature
Its anti-inflammatory properties make it effective in treating conditions like acne, rosacea, and eczema
It reported dose-dependent telomere length extension in normal cells, apparently through upregulation of hTERT and telomerase activity, while cancer cells appeared to rely more on alternative lengthening of telomeres pathways
It is different from TB-500 Research Peptide, different from GHRH analogues and different from metabolic receptor agonists
